Why the news release and why now?For the past couple of days I've been wondering why TLT released a study update now rather than in late November as expected. I've decided to believe the news release is signalling a material event. The material event is that the 12 underdosed patients will be included in the total evaluable patients. My guess is that this is under the direction of the FDA as part of the pre BTD submission consultations. The CR of the 32 optimized patients that have reached 450 days is 34%. The CR of the total treated patients including underdosed patients (42 patients in total) at day 450 is 33%. Not a significant difference. What is significant is the statistical level of confidence. Obviously one can be a lot more confident of a CR result in 42 patients than a CR in 32 patients. I believe this news release is under the direction of FDA guidance in the pre submission discussions and the BTD submission should occur in the near future. GLTA.